Journal
PROTEIN SCIENCE
Volume 16, Issue 5, Pages 983-989Publisher
WILEY
DOI: 10.1110/ps.072755707
Keywords
mevalonate kinase; GHMP kinase; allosteric inhibitor; antimicrobial target; diphosphomevalonate; Streptococcus pnuemoniae; crystal structure; mevalonate deficiency
Categories
Ask authors/readers for more resources
Streptococcus pneumoniae, a ubiquitous gram-positive pathogen with an alarming, steadily evolving resistance to frontline antimicrobials, poses a severe global health threat both in the community and in the clinic. The recent discovery that diphosphomevalonate ( DPM), an essential intermediate in the isoprenoid biosynthetic pathway, potently and allosterically inhibits S. pneumoniae mevalonate kinase ( SpMK) without affecting the human isozyme established a new target and lead compound for antimicrobial design. Here we present the crystal structure of the first S. pneumoniae mevalonate kinase, at a resolution of 2.5 angstrom and in complex with DPM . Mg2+ in the active- site cleft. Structural comparison of SpMK with other members of the GHMP kinase family reveals that DPM functions as a partial bisubstrate analog ( mevalonate linked to the pyrophosphoryl moiety of ATP) in that it elicits a ternary-complex like form of the enzyme, except for localized disordering in a region that would otherwise interact with the missing portion of the nucleotide. Features of the SpMK- binding pockets are discussed in the context of established mechanistic findings and inherited human diseases linked to MK deficiency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available